Novo Nordisk invests DKK1.5bn in new manufacturing facility in Denmark for haemophilia treatments
Will create around 100 new production and engineering jobs
Novo Nordisk has broken ground on a new DKK1.5bn (US$224m) facility which will produce active pharmaceutical ingredients for haemophilia products.
Approximately 100 new production and engineering jobs will be created at the new 7,500m2 facility in Kalundborg, Denmark where Novo Nordisk currently employs more than 2,800 people.
The company expects the facility to be approved and fully operational by 2020. It will produce APIs for NovoSeven, the Danish pharmaceutical company's recombinant treatment for patients with congenital haemophilia, which contains the active substance eptacog alfa, as well as future haemophilia products.
Henrik Wulff, Executive Vice President, Product Supply, Novo Nordisk, said: 'The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees.'
Established in 1969, the Kalundborg production site is Novo Nordisk's largest and has a total area of 1,000,000m2.